Inovio Pharmaceuticals Inc. INO, +6.58% is planning the first dosing of patients in a Phase 1 trial of its DNA vaccine candidate to treat COVID-19 on Monday, the company said in a statement. The vaccine, named INO-4800, has shown promising response in preclinical animal studies, the company said. The trial will involve up to 40 healthy volunteers at two trial locations in Phladelphia and Kansas City. Each participant will receive two doses four weeks apart, with data expected by late summer. The trial is being funded by the Coalition for Epidemic Preparedness Innovations (CEPI), an Oslo-based international organization. Inovio shares rose 7% premarket and have gained 135% in the year to date, while the S&P 500 SPX, -0.45% has fallen 23%.